AN2 Therapeutics (ANTX) Earnings Analysis
AN2 Therapeutics (ANTX) next reports earnings on 2026-08-11, consensus EPS -0.23 USD. Last quarter (2026-05-11) it missed with EPS -0.29 USD vs -0.23 USD est (-26.1%). It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E -4.45.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ANTX next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.23 USD |
| Revenue estimate | n/a |
ANTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.29 USD | -0.23 USD | -26.1% | Miss |
| 2026-03-17 | -0.29 USD | -0.24 USD | -20.8% | Miss |
| 2024-11-13 | -0.43 USD | -0.37 USD | -16.2% | Miss |
Beat rate: 0/3 (0%) over reported quarters with consensus data.
ANTX valuation and analyst view
| Trailing P/E | -4.45 |
|---|---|
| Trailing EPS | -1.01448 USD |
| Price / book | 2.04 |
| Dividend yield | 0.00% |
| Market cap | 0.13B |
| Analyst consensus | Buy (5 buy / 3 hold / 0 sell) |
| Avg price target | 9 USD |
Related research pages
Frequently asked questions
When is AN2 Therapeutics (ANTX)'s next earnings date?
AN2 Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.23 USD.
Did ANTX beat earnings last quarter?
In its 2026-05-11 report, ANTX posted EPS of -0.29 USD versus a -0.23 USD estimate — a miss of 26.1%.
What is ANTX's earnings track record?
Over the last 3 reported quarters with consensus data, ANTX beat estimates 0 times (0%).
What is ANTX's current P/E ratio and EPS?
ANTX trades at a trailing P/E of -4.45 on trailing EPS of -1.0144781501846925 USD.
What do analysts rate ANTX?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 9 USD.